SynthesisJournal of racial and ethnic health disparities2026
Evidence-Based Practice in Prescribing SGLT2i and GLP-1 RA Across Ethnic and Racial Groups: a Systematic Review and Meta-analysis of Observational Studies.
Synthesis in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Racial Disparities in SGLT2 Inhibitor Initiation Among Medicaid-Insured Adults With Type 2 Diabetes: A Retrospective Cohort Study.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe newer classes of anti-diabetes medications have additional cardiovascular and renal effects, and restricted access would contribute to diabetes-related healthcare disparities. Hence, a systematic review, and meta-analysis, was undertaken to determine the existence of racial and ethnic disparities in the uptake of SGLT2i or GLP-1 RA.
methodsThe search was performed using Scopus, Cochrane Central Registry of Controlled Trials, PubMed, and Web of Science databases. Eligibility to include the studies was assessed independently, and this review included observational studies. The necessary information was extracted using the Cochrane-modified data extraction form. The quality of the studies was assessed using the Newcastle-Ottawa scale. RevMan v5.4.1 was used to conduct the analysis. The certainty of the evidence was measured with GradePro.
resultsThe likelihood of prescription fills with SGLT2i and GLP-1 RA was lower among the Black population, with odds ratios (OR) of 0.81 (95% CI 0.75-0.88, p < 0.0001) for SGLT2i and 0.78 (95% CI 0.70-0.87, p < 0.0001) for GLP-1 RA when compared to White population. Additionally, Asian individuals and those classified under "Other" populations had a significant reduction in GLP-1 RA prescription fills, with odds ratios of 0.61 (95% CI 0.43-0.86) and 0.73 (95% CI 0.60-0.89), respectively. However, there was no significant difference in SGLT2i prescription fills among the Asian individuals (p = 0.56) or those in the "Other" population category (p = 0.51).
conclusionsThe extent of evidence-based practice in prescribing SGLT2i was significantly low among the Black population compared to patients who are Whites. The number of prescriptions filled by GLP-1 RA was significantly low among the Asian population, the Black population, and other populations. Thus, policymakers and clinicians must take the necessary initiatives to achieve pharmacoequity in managing T2DM with co-morbidity conditions.
Indexed as
Identifiers
40259185What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.